Aurore Desmons

Aurore Desmons

Auto-generated profile, based on publicly available information

Aurore Desmons

Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, Microbiota, Gut and Inflammation Laboratory, Hôpital Saint-Antoine, F-75012, Paris, France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2022 in Journal of Chromatography A
Verified
Journal Article
Open access
ADAurore Desmons
Aurore Desmons
LHLydie Humbert
Lydie Humbert
TEThibaut Eguether
Thibaut Eguether
PKPranvera Krasniqi
Pranvera Krasniqi
DRDominique Rainteau
Dominique Rainteau
ALAntonin Lamazière
Antonin Lamazière
Tryptophan, an essential amino acid, and its metabolites are involved in many physiological processes including neuronal functions, immune system, and gut homeostasis. Alterations to tryptophan metabolism are associated with various pathologies such as neurologic, psychiatric disorders, inflammatory bowel diseases (IBD), metabolic disorders, and cancer. It is consequently critical to develop a reliable, quantitative method for the analysis of tryptophan and its downstream metabolites from the kynurenine, serotonin, and indoles pathways. An LC-MS/MS method was designed for the analysis of tryptophan and 20 of its metabolites, without derivatization and performed in a single run. This method was validated for both serum and stool. The comparisons between serum and plasma, collected with several differing anticoagulants, showed significant differences only for serotonin. References values were established in sera and stools from healthy donors. For stool samples, as a proof of concept, the developed method was applied to a healthy control group and an IBD patient group. Results showed significant differences in the concentrations of tryptophan, xanthurenic acid, kynurenic acid, indole-3-lactic acid, and picolinic acid. This method allowed an extensive analysis of the three tryptophan metabolic pathways in two compartments. Beyond the application to IBD patients, the clinical use of this method is wide-ranging and may be applied to other pathological conditions involving tryptophan metabolism, such as neurological, psychiatric, or auto-inflammatory pathologies.

11 March 2022 in Cells
Verified
Journal Article
Open access
PDF file
DCDragos Ciocan
Dragos Ciocan
MSMADELEINE SPATZ
MADELEINE SPATZ
TNTrainel Nicolas
Trainel Nicolas
KHKévin Hardonnière
Kévin Hardonnière
SDSéverine DOMENICHINI
Séverine DOMENICHINI
ACAnne Marie Cassard-Doulcier
Anne Marie Cassard-Doulcier
Reshaping the intestinal microbiota by the ingestion of fiber, such as pectin, improves alcohol-induced liver lesions in mice by modulating bacterial metabolites, including indoles, as well as bile acids (BAs). In this context, we aimed to elucidate how oral supplementation of pectin affects BA metabolism in alcohol-challenged mice receiving feces from patients with alcoholic hepatitis. Pectin reduced alcohol liver disease. This beneficial effect correlated with lower BA levels in the plasma and liver but higher levels in the caecum, suggesting that pectin stimulated BA excretion. Pectin modified the overall BA composition, favoring an augmentation in the proportion of hydrophilic forms in the liver, plasma, and gut. This effect was linked to an imbalance between hydrophobic and hydrophilic (less toxic) BAs in the gut. Pectin induced the enrichment of intestinal bacteria harboring genes that encode BA-metabolizing enzymes. The modulation of BA content by pectin inhibited farnesoid X receptor signaling in the ileum and the subsequent upregulation of Cyp7a1 in the liver. Despite an increase in BA synthesis, pectin reduced BA serum levels by promoting their intestinal excretion. In conclusion, pectin alleviates alcohol liver disease by modifying the BA cycle through effects on the intestinal microbiota and enhanced BA excretion.

19 April 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
TMTarek Mahdi
Tarek Mahdi
ADAurore Desmons
Aurore Desmons
PKPranvera Krasniqi
Pranvera Krasniqi
JLJean-Marc Lacorte
Jean-Marc Lacorte
NKNathalie Kapel
Nathalie Kapel
TEThibaut Eguether
Thibaut Eguether
Short chain fatty acids (SCFAs) are primarily produced in the caecum and proximal colon via the bacterial fermentation of undigested carbohydrates that have avoided digestion in the small intestine. Increasing evidence supports the critical role that SCFAs play in health and homeostasis. Microbial SCFAs, namely butyric acid, serve as a principal energy source for colonocytes, and their production is essential for gut integrity. A direct link between SCFAs and some human pathological conditions, such as inflammatory bowel disease, irritable bowel syndrome, diarrhea, and cancer, has been proposed. The direct measurement of SCFAs in feces provides a non-invasive approach to demonstrating connections between SCFAs, microbiota, and metabolic diseases to estimate their potential applicability as meaningful biomarkers of intestinal health. This study aimed to adapt a robust analytical method (liquid–liquid extraction, followed by isobutyl chloroformate derivatization and GC–MS analysis), with comparable performances to methods from the literature, and to use this tool to tackle the question of pre-analytical conditions, namely stool processing. We focused on the methodology of managing stool samples before the analysis (fresh stool or dilution in either ethanol/methanol, lyophilized stool, or RNAlater®), as this is a significant issue to consider for standardizing results between clinical laboratories. The objective was to standardize methods for future applications as diagnostic tools. In this paper, we propose a validated GC–MS method for SCFA quantification in stool samples, including pre- and post-analytical comparison studies that could be easily used for clinical laboratory purposes. Our results show that using lyophilization as a stool-processing method would be the best method to achieve this goal.

5 October 2026 in Green Chemistry
Verified
Journal Article
Open access
MRMd Masudur Rahman
Md Masudur Rahman
AAAdel Bou Alia
Adel Bou Alia
MCMinna Choi
Minna Choi
NTNicolas Trainel
Nicolas Trainel
PKPranvera Krasniqi
Pranvera Krasniqi
FLFrançois-Xavier LEGRAND
François-Xavier LEGRAND
Acute oral exposure to ChCl : urea DES induces gut microbiota dysbiosis, disrupts the bile acid-FXR-liver axis, and triggers subclinical hepatic inflammation, revealing critical toxicological endpoints overlooked by classical safety markers.

25 September 2026 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
CRClaudia Ravelli
Claudia Ravelli
DFDominique Farabos
Dominique Farabos
OCOphélie Chaussenery
Ophélie Chaussenery
IFInès Fayache
Inès Fayache
FRFlorence Renaldo
Florence Renaldo
ADAurore Desmons
Aurore Desmons
Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare neurometabolic disorder requiring early and accurate diagnosis, especially with the implementation of gene therapy. Herein, we developed and thoroughly validated a rapid and reliable LC-MS/MS method for the quantification of 3-O-methyldopa (3-OMD) in dried blood spots (DBS), offering a robust, sensitive, and minimally invasive alternative to cerebrospinal fluid analysis for the diagnosis of AADC deficiency. Age-specific 3-OMD reference intervals and diagnostic cut-off values were defined to determine diagnostic decision thresholds for AADC deficiency in a pediatric population. The proposed upper cut-offs were 2.89 µmol/L for neonates, 1.03 µmol/L for children aged 28 days to 10 years, and 0.72 µmol/L for children older than 10 years. For the first time, we report longitudinal 3-OMD profiles in AADC patients undergoing gene therapy, offering preliminary insights into biomarker kinetics post-treatment. In patients treated with gene therapy, 3-OMD levels decreased over time but remained above the established reference ranges. Overall, the findings support the clinical implementation of blood-based 3-OMD quantification for diagnosis of AADC deficiency. This method could enable rapid diagnosis in the pediatric population presenting with neurological symptoms that are not always clearly indicative of AADC deficiency. Further research involving larger patient cohorts, extended follow-up periods, and integration of clinical outcome measures is warranted to better define the role of 3-OMD in therapeutic monitoring and to identify additional biomarkers that may further optimize therapeutic strategies.